<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421434</url>
  </required_header>
  <id_info>
    <org_study_id>RM01-3036</org_study_id>
    <nct_id>NCT00421434</nct_id>
  </id_info>
  <brief_title>Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C</brief_title>
  <acronym>STEALTHC-1</acronym>
  <official_title>Randomized Study of Nitazoxanide-Peginterferon, Nitazoxanide-Peginterferon-Ribavirin and Peginterferon-Ribavirin in the Treatment of Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Romark Laboratories L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Romark Laboratories L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of
      nitazoxanide-peginterferon and nitazoxanide-peginterferon-ribavirin combination regimens
      compared to the standard of care (peginterferon-ribavirin) in treating chronic hepatitis C
      genotype 4. The study will also evaluate the effect of the studied treatment regimens on end
      of treatment virologic response, ALT normalization and safety parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virologic response</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>End of treatment virologic response</measure>
    <time_frame>At the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early virologic response</measure>
    <time_frame>After 12 weeks of combination therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid virologic response</measure>
    <time_frame>After 4 weeks of combination therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT normalization</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Nitazoxanide-Peginterferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitazoxanide-Peginterferon-Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight &lt;75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon-Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight &lt;75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.</description>
    <arm_group_label>Nitazoxanide-Peginterferon</arm_group_label>
    <arm_group_label>Nitazoxanide-Peginterferon-Ribavirin</arm_group_label>
    <other_name>Alinia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.</description>
    <arm_group_label>Nitazoxanide-Peginterferon</arm_group_label>
    <arm_group_label>Nitazoxanide-Peginterferon-Ribavirin</arm_group_label>
    <other_name>PEGASYS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.</description>
    <arm_group_label>Peginterferon-Ribavirin</arm_group_label>
    <other_name>PEGASYS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Oral ribavirin 1000 mg (body weight &lt;75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.</description>
    <arm_group_label>Nitazoxanide-Peginterferon-Ribavirin</arm_group_label>
    <other_name>COPEGUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Oral ribavirin 1000 mg (body weight &lt;75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.</description>
    <arm_group_label>Peginterferon-Ribavirin</arm_group_label>
    <other_name>COPEGUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years.

          -  Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme
             immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification
             of HCV RNA.

          -  Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral
             hepatitis.

          -  HCV genotype 4.

        Exclusion Criteria:

          -  Patients who have previously failed to respond to ≥12 weeks of peginterferon-ribavirin
             combination therapy.

          -  Females who are either pregnant, breast-feeding or not using birth control and are
             sexually active.

          -  Males whose female partners are pregnant.

          -  Patients with other causes of liver disease (i.e., autoimmune hepatitis, decompensated
             liver disease).

          -  Patients co-infected with hepatitis A virus, hepatitis B virus or hepatitis D virus.

          -  Patients with a history of alcoholism or with an alcohol consumption of &gt;40 grams per
             day.

          -  Patients with hemoglobinopathies (i.e., thalassemia major, sickle-cell anemia).

          -  Patients with any concomitant condition that, in the opinion of the investigator,
             would preclude evaluation of response or make it unlikely that the contemplated course
             of therapy and follow-up could be completed.

          -  History of hypersensitivity or intolerance to any of the excipients comprising the
             nitazoxanide tablets, peginterferon alfa-2a injectionable solution or ribavirin
             tablets.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yehia El-Gohary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Tropical Medicine &amp; Infectious Diseases, Alexandria University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asem Elfert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Tropical Medicine &amp; Infectious Diseases, Tanta University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Tropical Medicine &amp; Infectious Diseases, Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Tropical Medicine &amp; Infectious Diseases, Tanta University School of Medicine</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2007</study_first_posted>
  <last_update_submitted>September 23, 2008</last_update_submitted>
  <last_update_submitted_qc>September 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Romark Laboratories, L.C.</name_title>
    <organization>Romark Laboratories, L.C.</organization>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

